BIOTE CORP -A (BTMD) Stock Fundamental Analysis
USA - NASDAQ:BTMD - US0906831039 - Common Stock
2.6 USD
-0.04 (-1.52%)
2.6 USD
0 (0%)
We assign a fundamental rating of 5 out of 10 to BTMD. BTMD was compared to 191 industry peers in the Pharmaceuticals industry. BTMD has an average financial health and profitability rating. A decent growth rate in combination with a cheap valuation! Better keep an eye on BTMD.
1. Profitability
1.1 Basic Checks
BTMD had positive earnings in the past year.
BTMD had a positive operating cash flow in the past year.
Of the past 5 years BTMD 4 years were profitable.
Of the past 5 years BTMD 4 years had a positive operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of 29.87%, BTMD belongs to the top of the industry, outperforming 98.95% of the companies in the same industry.
The Return On Invested Capital of BTMD (51.55%) is better than 99.48% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 29.87% | ||
| ROE | N/A | ||
| ROIC | 51.55% |
ROA(3y)1.27%
ROA(5y)30.69%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin of BTMD (15.73%) is better than 89.01% of its industry peers.
BTMD's Profit Margin has declined in the last couple of years.
With an excellent Operating Margin value of 17.79%, BTMD belongs to the best of the industry, outperforming 86.39% of the companies in the same industry.
BTMD's Operating Margin has declined in the last couple of years.
BTMD has a better Gross Margin (71.89%) than 79.06% of its industry peers.
BTMD's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 17.79% | ||
| PM (TTM) | 15.73% | ||
| GM | 71.89% |
OM growth 3Y-13.56%
OM growth 5Y-5.58%
PM growth 3Y-59.09%
PM growth 5Y-39.26%
GM growth 3Y2.76%
GM growth 5Y3.16%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), BTMD is creating value.
The number of shares outstanding for BTMD has been reduced compared to 1 year ago.
Compared to 1 year ago, BTMD has a worse debt to assets ratio.
2.2 Solvency
BTMD has an Altman-Z score of 2.35. This is not the best score and indicates that BTMD is in the grey zone with still only limited risk for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 2.35, BTMD is in the better half of the industry, outperforming 67.02% of the companies in the same industry.
The Debt to FCF ratio of BTMD is 4.35, which is a neutral value as it means it would take BTMD, 4.35 years of fcf income to pay off all of its debts.
BTMD has a Debt to FCF ratio of 4.35. This is amongst the best in the industry. BTMD outperforms 83.77% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 4.35 | ||
| Altman-Z | 2.35 |
ROIC/WACC5.77
WACC8.93%
2.3 Liquidity
A Current Ratio of 0.98 indicates that BTMD may have some problems paying its short term obligations.
The Current ratio of BTMD (0.98) is worse than 82.20% of its industry peers.
BTMD has a Quick Ratio of 0.98. This is a bad value and indicates that BTMD is not financially healthy enough and could expect problems in meeting its short term obligations.
BTMD's Quick ratio of 0.74 is on the low side compared to the rest of the industry. BTMD is outperformed by 84.82% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.98 | ||
| Quick Ratio | 0.74 |
3. Growth
3.1 Past
BTMD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 190.00%, which is quite impressive.
The earnings per share for BTMD have been decreasing by -48.53% on average. This is quite bad
Looking at the last year, BTMD shows a small growth in Revenue. The Revenue has grown by 6.38% in the last year.
BTMD shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 12.38% yearly.
EPS 1Y (TTM)190%
EPS 3Y-71.33%
EPS 5Y-48.53%
EPS Q2Q%-33.33%
Revenue 1Y (TTM)6.38%
Revenue growth 3Y12.26%
Revenue growth 5Y12.38%
Sales Q2Q%-6.67%
3.2 Future
Based on estimates for the next years, BTMD will show a very strong growth in Earnings Per Share. The EPS will grow by 42.78% on average per year.
The Revenue is expected to grow by 6.82% on average over the next years.
EPS Next Y166.59%
EPS Next 2Y24.94%
EPS Next 3Y24.88%
EPS Next 5Y42.78%
Revenue Next Year-2.93%
Revenue Next 2Y0.89%
Revenue Next 3Y2.93%
Revenue Next 5Y6.82%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 2.99 indicates a rather cheap valuation of BTMD.
97.91% of the companies in the same industry are more expensive than BTMD, based on the Price/Earnings ratio.
BTMD is valuated cheaply when we compare the Price/Earnings ratio to 25.91, which is the current average of the S&P500 Index.
A Price/Forward Earnings ratio of 7.57 indicates a rather cheap valuation of BTMD.
Based on the Price/Forward Earnings ratio, BTMD is valued cheaply inside the industry as 92.67% of the companies are valued more expensively.
Compared to an average S&P500 Price/Forward Earnings ratio of 34.57, BTMD is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 2.99 | ||
| Fwd PE | 7.57 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, BTMD is valued cheaper than 94.76% of the companies in the same industry.
97.91% of the companies in the same industry are more expensive than BTMD, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 3.71 | ||
| EV/EBITDA | 6.68 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
BTMD has a very decent profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as BTMD's earnings are expected to grow with 24.88% in the coming years.
PEG (NY)0.02
PEG (5Y)N/A
EPS Next 2Y24.94%
EPS Next 3Y24.88%
5. Dividend
5.1 Amount
No dividends for BTMD!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
2.6
-0.04 (-1.52%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners64.32%
Inst Owner Change0.12%
Ins Owners9.75%
Ins Owner Change0.43%
Market Cap128.54M
Revenue(TTM)197.19M
Net Income(TTM)31.31M
Analysts81.82
Price Target5.51 (111.92%)
Short Float %3.09%
Short Ratio6.63
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)318.36%
Min EPS beat(2)178.65%
Max EPS beat(2)458.07%
EPS beat(4)3
Avg EPS beat(4)223.56%
Min EPS beat(4)-1.96%
Max EPS beat(4)458.07%
EPS beat(8)5
Avg EPS beat(8)86.5%
EPS beat(12)6
Avg EPS beat(12)-127.37%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-0.83%
Min Revenue beat(2)-3.31%
Max Revenue beat(2)1.66%
Revenue beat(4)1
Avg Revenue beat(4)-2.07%
Min Revenue beat(4)-4.66%
Max Revenue beat(4)1.66%
Revenue beat(8)2
Avg Revenue beat(8)-2.3%
Revenue beat(12)4
Avg Revenue beat(12)-1.33%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-18.93%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-54.83%
EPS NY rev (1m)0%
EPS NY rev (3m)-5.74%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-8.94%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-5.86%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 2.99 | ||
| Fwd PE | 7.57 | ||
| P/S | 0.65 | ||
| P/FCF | 3.71 | ||
| P/OCF | 3.1 | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | 6.68 |
EPS(TTM)0.87
EY33.46%
EPS(NY)0.34
Fwd EY13.21%
FCF(TTM)0.7
FCFY26.93%
OCF(TTM)0.84
OCFY32.27%
SpS4.03
BVpS-1.72
TBVpS-2.01
PEG (NY)0.02
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 29.87% | ||
| ROE | N/A | ||
| ROCE | 65.25% | ||
| ROIC | 51.55% | ||
| ROICexc | 80.7% | ||
| ROICexgc | 137.37% | ||
| OM | 17.79% | ||
| PM (TTM) | 15.73% | ||
| GM | 71.89% | ||
| FCFM | 17.39% |
ROA(3y)1.27%
ROA(5y)30.69%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y-32.05%
ROICexgc growth 5YN/A
ROICexc growth 3Y-33.38%
ROICexc growth 5YN/A
OM growth 3Y-13.56%
OM growth 5Y-5.58%
PM growth 3Y-59.09%
PM growth 5Y-39.26%
GM growth 3Y2.76%
GM growth 5Y3.16%
F-Score6
Asset Turnover1.9
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 4.35 | ||
| Debt/EBITDA | 2.98 | ||
| Cap/Depr | 184.76% | ||
| Cap/Sales | 3.45% | ||
| Interest Coverage | 3.69 | ||
| Cash Conversion | 106.02% | ||
| Profit Quality | 110.56% | ||
| Current Ratio | 0.98 | ||
| Quick Ratio | 0.74 | ||
| Altman-Z | 2.35 |
F-Score6
WACC8.93%
ROIC/WACC5.77
Cap/Depr(3y)122.96%
Cap/Depr(5y)152.59%
Cap/Sales(3y)2.04%
Cap/Sales(5y)2.01%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)190%
EPS 3Y-71.33%
EPS 5Y-48.53%
EPS Q2Q%-33.33%
EPS Next Y166.59%
EPS Next 2Y24.94%
EPS Next 3Y24.88%
EPS Next 5Y42.78%
Revenue 1Y (TTM)6.38%
Revenue growth 3Y12.26%
Revenue growth 5Y12.38%
Sales Q2Q%-6.67%
Revenue Next Year-2.93%
Revenue Next 2Y0.89%
Revenue Next 3Y2.93%
Revenue Next 5Y6.82%
EBIT growth 1Y-11.91%
EBIT growth 3Y-2.97%
EBIT growth 5Y6.11%
EBIT Next Year32.82%
EBIT Next 3Y16.27%
EBIT Next 5Y14.88%
FCF growth 1Y14.31%
FCF growth 3Y8.58%
FCF growth 5Y10.09%
OCF growth 1Y28.77%
OCF growth 3Y10.29%
OCF growth 5Y12.28%
BIOTE CORP -A / BTMD FAQ
Can you provide the ChartMill fundamental rating for BIOTE CORP -A?
ChartMill assigns a fundamental rating of 5 / 10 to BTMD.
What is the valuation status of BIOTE CORP -A (BTMD) stock?
ChartMill assigns a valuation rating of 9 / 10 to BIOTE CORP -A (BTMD). This can be considered as Undervalued.
Can you provide the profitability details for BIOTE CORP -A?
BIOTE CORP -A (BTMD) has a profitability rating of 6 / 10.
What is the expected EPS growth for BIOTE CORP -A (BTMD) stock?
The Earnings per Share (EPS) of BIOTE CORP -A (BTMD) is expected to grow by 166.59% in the next year.
Can you provide the dividend sustainability for BTMD stock?
The dividend rating of BIOTE CORP -A (BTMD) is 0 / 10 and the dividend payout ratio is 0%.